SelectScience
Join Free
Accelerating Science
NewsLife Sciences

The Rise of Companion Diagnostic Tests for Personalized Cancer Treatment

SelectScience

A look at some of the available companion diagnostics for breast, lung and colorectal cancer

18 Feb 2016
Sonia Nicholas
Managing Editor and Clinical Lead

Editorial article

Image of cancer cells

According to the FDA, a ‘companion diagnostic device can be an in vitro diagnostic device or an imaging tool that provides information that is essential for the safe and effective use of a corresponding therapeutic product’1.

The first companion diagnostic test was launched in 1998 to identify breast cancer patients suitable for treatment with Herceptin® (trastuzumab). There was considerable scepticism and concern around these tests, however their success paved the way for an explosion of activity in the field of companion diagnostics.

Regulations and risk

Companion diagnostic tests are typically classified as Class III diagnostic tests, whereas IVD diagnostic tests are usually classified as Class II. This extra layer of complexity and regulation is in place because companion diagnostic tests are designed to predict patient responses to medication and as a result can be high risk.

In 2006 there were 6 companion diagnostic tests available on the market, by 2012 this number had grown to 63 available tests. This number continues to grow and reflects the increasing need for personalized medicine in healthcare. In this article we look at some of the companion diagnostic tests available for breast, lung and colorectal cancer.

Breast Cancer

Image of a breast mammogram used to detect breast cancer

Approximately 1 in 4 breast cancer patients are positive for human epidermal growth factor positive (HER2+)2. HER2+ is present on the surface of normal breast cells, however HER2+ patients have very high numbers of these receptors which stimulate the cancer cells to divide and grow. Targeted therapy with Herceptin can be very effective in HER2+ patients. Herceptin attaches itself to the HER2 receptors and blocks them from receiving growth signals thus stopping or slowing the tumor growth. Herceptin therapy cannot be prescribed unless the patient has been tested to check there HER2 level.

There are a number of companion diagnostic tests available on the market to test for HER2 and indicate effective use of Herceptin. These include:

INFORM HER-2/NEU, Ventana Medical Systems Inc. - a fluorescence in situ hybridization (FISH) DNA probe assay that determines the qualitative presence of Her-2/Neu gene amplification on formalin-fixed, paraffin embedded human breast tissue.

PATHVYSION HER-2 DNA Probe Kit, Abbott Molecular - designed to detect amplification of the HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed, paraffin-embedded human breast cancer tissue specimens.

SPOT-LIGHT HER2 CISH Kit, Life Technologies - quantitatively determines HER2 gene amplification in formalin-fixed, paraffin-embedded (FFPE) breast carcinoma tissue sections using Chromogenic In Situ Hybridization (CISH) and brightfield microscopy.

Non-Small Cell Lung Cancer (NSCLC)

Epidermal growth factor receptor (EGFR) allows normal cells to grow and divide. Approximately 15% of NSCLC patients have an EGFR mutation leading to too many of these receptors being present and causing uncontrolled growth and division. Tyrosine kinase inhibitors can block EGFR from functioning, thus stopping some tumors from growing. There are a number of companion diagnostic tests available to help predict the effectiveness of use of some TKI’s such as erlotinib and gefitinib.

cobas EGFR Mutation Test, Roche Molecular Systems - a real-time PCR test for the qualitative detection of exon 19 deletions and exon 21 (L858R) substitution mutations of the epidermal growth factor receptor (EGFR) gene in DNA derived from formalin-fixed paraffin-embedded (FFPET) human non-small cell lung cancer (NSCLC) tumor tissue. The test is intended to be used as an aid in selecting patients with NSCLC for whom Tarceva® (erlotinib), an EGFR tyrosine kinase inhibitor (TKI), is indicated.

therascreen EGFR RGQ PCR Kit, QIAGEN - a real-time PCR test for the qualitative detection of exon 19 deletions and exon 21 (L858R) substitution mutations of the epidermal growth factor receptor (EGFR) gene in DNA derived from formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tumor tissue. The test is intended to be used to select patients with NSCLC for whom GILOTRIF (afatinib), an EGFR tyrosine kinase inhibitor (TKI), is indicated.

ALK mutations are found in 3-7% of lung cancer tumors. They are often found in lapsed, light smokers or people who have never smoked. Crizotinib is an ALK inhibitor that can be effective in patients with ALK mutations.

VENTANA ALK (D5F3) CDx Assay, Ventana Medical Systems - qualitative detection of the anaplastic lymphoma kinase (ALK) protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) tissue stained with a BenchMark XT automated staining instrument. Identifies patients eligible for treatment with XALKORI® (crizotinib).

Colorectal cancer

Approximately 40% of patients with colorectal cancer have the KRAS mutation3. Patients who have the KRAS mutation do not respond to epidermal growth factor receptor (EGFR) inhibitors such as cetuximab (Erbitux) and panitumumab (Vectibix). Companion diagnostic tests highlight wild-type KRAS patients (patients without the KRAS mutation) who are more likely to benefit from EGFR inhibitors.

The cobas® KRAS Mutation Test, Roche Molecular Systems, Inc. - a real-time PCR test for the detection of KRAS gene mutations in DNA derived from formalin-fixed paraffin-embedded human colorectal cancer tumor tissue. Intended to aid in the treatment with Erbitux® (cetuximab) or with Vectibix® (panitumumab). Specimens are processed using the cobas® DNA Sample Preparation Kit for manual sample preparation and the cobas z 480 analyzer for automated amplification and detection.

therascreen KRAS RGQ PCR Kit - a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of seven somatic mutations in the human KRAS oncogene, using DNA extracted from formalin-fixed paraffin-embedded (FFPE), colorectal cancer (CRC) tissue. Used to identify patients for treatment with Erbitux (cetuximab) and Vectibix (panitumumab).

The future

Companion diagnostics are an essential component of personalized medicine. In the future, the number of available tests will continue to increase and the application areas will continue to expand beyond oncology.

References:

1. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm
2. http://www.herceptin.com/breast/herceptin
3. http://www.cancercare.org/publications/93-colorectal_cancer_new_tools_for_making_decisions_about_treatment

Links

SelectScienceCompany website

Tags

HematologyIn Haematology / Hematology, complete blood cell counts (or full blood counts) are obtained using automated blood count analyzers to enumerate blood cell types.  Hematology also encompasses haemostasis and coagulation, thrombophilia and hemophilia, plasma viscosity and ESR analysis, hemoglobinopathies, cell morphology and haematinic measurement.ImmunologyImmunological techniques measure and characterize immune responses. Immunology kits and analysis systems often use techniques such as ELISA, radioimmunoassay (RIA) and immunodiffusion assays, Immunohistochemistry, and flow cytometry. Immunologists use equipment such as flow Cytometers, plate readers, plate washers and fluorescent microscopes.Cell-Based AssaysCell-based assays are used to monitor the presence, quantity and activities of a desired cellular analyte including drug molecules or biomarkers. This can reveal information on cell health (apoptosis, cytotoxicity, viability and proliferation assays), cell metabolism, cell migration and cell signaling mechanisms. Find the best cell-based assay products, kits and equipment with our peer reviewed product directory: compare products, check customer reviews and receiving pricing direct from manufacturers.DNA / RNA Extraction and PurificationPurified DNA and RNA are required for numerous downstream molecular biology applications. Consequently, the importance of high-quality DNA/RNA extraction and purification equipment cannot be underestimated. Many purification kits are available and are typically optimized for nucleic acid type and source, including plasmid DNA, genomic DNA, mRNA, RNA and viral nucleic acid purification kits. Automated extraction and purification of nucleic acids can be implemented with magnetic bead separator instruments or high-throughput purification workstations. Find the best DNA/RNA extraction and purification equipment in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Point-of-CarePoint-of-Care Testing (POCT) or Near Patient Testing (NPT) products are available for urine, blood and other clinical chemistry analyses. POCT includes: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing (PT / INR), rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Clinical ChemistryBiochemistry (or clinical chemistry) involves the analysis of bodily fluids using chemical tests. Techniques used include HPLC, chromatography, spectroscopy, mass spectrometry, immunochemical, electrophoresis, turbidometric / spectrophotometric assay, MRI and ISE analysis. Tests are often carried out on plasma or serum but urine (urinalysis) and fecal specimens are also processed.Clinical GeneticsMolecular Genetics covers the analysis of hereditary genetic disease and chromosomal abnormalities. Genetics can be analysed using DNA, RNA, and protein microarrays, PCR, RT PCR and DNA sequencing. Genetic equipment includes genetic workstations, thermal cyclers, cooling blocks and electrophoresis products. Diagnostic kits are used for DNA / RNA extraction and purification.Cancer DiagnosticsThere are a wide variety of diagnostic tests for cancer available, and this range continues to expand as our knowledge of cancer improves. Current diagnostic methods include biopsy, imaging and blood tests for known biomarkers. New methods in research development include liquid biopsies and cancer breathalyzers.

Related articles

The Rise of Companion Diagnostic Tests for Personalized Cancer Treatment